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Abstract
Background: Health care workers (HCWs) are a group at risk of latent tuberculosis infection (LTBI). The aims of this study
were to determine IFN-c response by QuantiFERON-TB GOLD In Tube (QFN-G-IT) and T-SPOT.TB in HCWs, comparing the
results with tuberculin skin test (TST); and to analyze the capacity of IFN-c tests to detect recent versus remote LTBI with a
prolonged stimulation test (PST).
Methodology/Principal Findings: A total of 147 HCWs were enrolled; 23 of whom were BCG vaccinated. 95 HCWs (64.6%)
had a previous positive TST and were not retested; and 52 HCWs had a previous negative TST or were tested for the first
time. When we analysed individuals without previous positive TST, the number of positive results for T-SPOT.TB was 12/52
(23.1%); and for QFN-G-IT, 9/52 (17.3%). The global concordance (k) between T-SPOT.TB and QFN-G-IT with TST was 0.754
and 0.929 respectively. Of individuals with previous positive TST, T-SPOT.TB and QFN-G-IT were negative in 51.6% (49/95)
and 62.1% (59/95) respectively, decreasing the concordance to 0.321 and 0.288, respectively. In non-BCG vaccinated HCWs
with previous positive TST a positive IFN-c test was associated with degree of exposure and diameter of TST. PST was
performed in 24 HCW with previous positive TST and negative IFN-c tests. PST was developed in 3 cell cultures stimulated
with medium alone, ESAT-6 and CFP-10, respectively. In the third and sixth day of incubation period, part of the
supernatants were replaced with complete medium supplemented with (rIL)-2. On day 9, ELISPOT assay was performed. In
14 samples PST was not valid due to not having enough cells. In 8 cases, the response was negative, and in 2 cases positive,
suggesting that these patients were infected with Mycobacterium tuberculosis in some point in the past.
Conclusions: Both IFN-c tests showed a similar number of positive results, and concordance between the tests was
excellent. None of the tests was affected by prior BCG vaccination. IFN-c tests are a useful tool for detecting recent infection
in HCW population.
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Introduction
Health care workers (HCWs) are one of the groups at risk of
Mycobacterium tuberculosis infection through occupational exposure
[1]. However, the risk varies widely among the various
occupational groups and according to their exposure to active
tuberculosis (TB) patients. Therefore, the screening of HCWs for
latent tuberculosis infection (LTBI) is crucial in an infection
control program [2]. Periodical tuberculin skin testing (TST) has
been recommended as part of surveillance [3].
However, TST has some known limitations. TST measures cell-
mediated immunity in the form of a delayed-type hypersensitivity
response to the purified protein derivative (PPD) [4]. However, its
specificity is limited due to PPD cross reactivity with the
vaccination strain of Mycobacterium bovis bacilli Calmette-Gue ´rin
(BCG), and several non-tuberculous mycobacteria (NTM) [5].
Therefore, individuals sensitized by previous exposures to NTM or
vaccinated with BCG may respond immunologically to PPD.
Tests for in vitro diagnosis of LTBI based on the measurement of
interferon-gamma (IFN-c) production from peripheral blood
mononuclear cells (PBMCs) and whole blood in response to
specific M. tuberculosis secreted antigens have been developed. The
recent use of the 6-kD M. tuberculosis early-secreted antigenic target
protein (ESAT-6) and the 10-kD culture filtrate protein (CFP-10)
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in RD11, absent in the BCG strain and in the majority of NTM as
stimulating antigens has improved the specificity of the tests.
On the basis of this technology, two commercial IFN-c tests are
essentially available: QuantiFERON-TB Gold In Tube assay (QFN-G-
IT) (Cellestis Limited, Carnegie, Victoria, Australia) and T-
SPOT.TB assay (Oxford Immunotec, Abingdon, UK). Both tests
have received the final approval from the US Food and Drug
Administration (FDA) as a tool for diagnosing M. tuberculosis infection.
There are some differences between the two tests. QFN-G-IT test is
whole blood assay that detects IFN-c produced by T cells in response
to ESAT-6, CFP-10 and TB7.7 using an enzyme-linked immuno-
sorbent assay (ELISA) to measure IFN-c concentrations in
supernatants. In contrast, T-SPOT.TB detects the number of IFN-
c producing T cells after stimulating a definite number of isolated
peripheral blood mononuclear cells with ESAT-6 and CFP-10 by
means of an enzyme-linked immunospot assay (ELISPOT). In
commercially available tests, the whole blood and the isolated T cells
are short-stimulated with the specific antigens (16–24 h).
Since the development of the IFN-c assays, promising results in
diagnosing LTBI [8–15] and active TB [12,16,17] have been
published. IFN-c test results are not affected by BCG vaccination
or infection by the most common NTM, and its results have shown
to be closer than TST in relation to the degree of exposure to M.
tuberculosis [14,18,19]. In addition, in a large-scale cohort studies
recently published [20–22], positive IFN-c assays predicted
development of active TB in individuals with recent TB contact.
However, limited information is available on the performance of
the IFN-c tests, specially T-SPOT.TB in occupational medicine,
when used for screening of HCWs [23–28]. No head-to-head
comparisons between the two available IFN-c tests have been
performed in HCWs.
On the other hand, the IFN-c assays are thought to reflect more
recent, rather than remote TB infections. This is because activated
lymphocytes and effector T cells that produce IFN-c persist for a
limited time in the circulation once the antigen is cleared [29]. It is
thought that central memory T cells, but not effector ones, may
take several days (rather than hours) to produce effector cytokines
[30,31]. Therefore, contrary to the findings of the TST, in cases of
remote infection, the IFN-c level did not increase during the short
period of exposure to the antigen in the ex vivo IFN-c assay at
baseline.
In the present study we investigated the performance of both
commercially available IFN-c tests (QFN-G-IT and T-SPOT.TB)
and TST for detecting LTBI in HCWs. Concordance between
both test results and association with known risk factors for LTBI
were studied. We have also analyzed the capacity of the IFN-c
tests to detect recent versus remote TB infection, assessing the
effector and memory T cell profiles by means of a prolonged
stimulation test.
Materials and Methods
Study design and setting
We conducted a cross-sectional study from November 2004 to
July 2005 at the Hospital Universitari Germans Trias i Pujol in
Badalona, Barcelona, Spain. This is a general hospital with more
than 600 beds. Approximately fifty TB patients are treated each
year at the hospital and the estimated community incidence of TB
is 18.6/100.000 habitants [32].
Study Population
HCWs were recruited in the course of the routine examinations
at the time of the study. HCWs were not enrolled consecutively.
Each participant gave written informed consent. The study was
approved by the Ethics Committee of the Hospital Universitari
Germans Trias i Pujol. Information on the following variables was
gathered using a standardised questionnaire: age, gender, reason
for testing, degree of occupational exposure to TB (with High
being defined as HCWs from wards with$5 contagious patients
per year, HCWs from microbiology laboratory and autopsy wards,
and from emergency departments; Medium as HCWs from wards
with 2 to 4 contagious patients per year; and Low as HCWs from
wards with a maximum of 1 contagious patient per year [33]),
BCG vaccination and BCG scar, prior TST (date and result), job
category, service and years in the health profession.
Tuberculin skin test
All new HCWs, who did not have a documented TST result,
are tested with the TST during the routine examination at the
time of employment in the Preventive Medicine Department [34].
If HCWs had a previous positive TST, we took note of the place
and the year, but they were no retested. The Spanish national
guideline only recommend repeating TST in HCWs with a
previous negative TST [34]. TST was performed by the Mantoux
method using 2-TU of PPD RT23 (Statens Serum Institut,
Copenhagen, Denmark). Induration was measured 48–72 h after
the application. Following Spanish national guideline a diameter
equal or greater than 5 mm was considered positive (in BCG
vaccinated equal or more than 15 mm) [34]. To reduce the risk of
confusion between a booster effect and tuberculin conversion on
subsequent testing, individuals with negative initial test results
were re-tested within 7 to 10 days and the results of this second test
were recorded as the definitive result (two-step tuberculin testing
procedure) [35]. TST was administered and read by experienced
HCWs. Blood for IFN-c tests was collected before TST
application.
T-SPOT.TB
Briefly, eight millilitres of blood was drawn from each subject by
venopuncture in a vacutainer CPT tube (Beckton Dickinson
Diagnostics, Franklin Lakes, NJ). PBMCs were isolated by
centrifugation. After centrifugation, PBMCs were washed with
GIBCO RPMI 1640 medium (Invitrogen, Auckland, N.Z.) and
finally, were re-suspended in GIBCO AIM-V (Invitrogen, Auck-
land, N.Z.). The test was performed following manufacturer’s
recommendations. Four wells with a membrane pre-coated with
monoclonal antibody to IFN-c were used for each subject. The
assay requires a total of 250,000 viable cells per well. Cells were
stimulated in each well with medium alone (as nil control),
phytohaemagglutinin (as positive control) and different peptide
panels from the specific MTB antigens ESAT-6 (panel A) and
CFP-10 (panel B). Plates were incubated for 16–20 hours at 37uC
with 5%CO2. After the incubation, wells were washed four times
with PBS and incubated for 1 hour at 2–8uC with a monoclonal
antibody to IFN-c conjugated with alkaline-phosphatase. After
another four washing steps and adding a chromogenic substrate,
the presence of reactive antigen specific T cells was revealed as a
spot on the well.
Spots were scored by an automated AID ELISPOT plate reader
(Lector AID Elispots, Autoimmun Diagnostiks GMBH, Germany).
All readings were also manually verified. Subjects were considered
positive if there was a positive response to one or both antigen
panels. Test wells were scored as positive if they contained at least
six spot forming cells (SFC) more than in the nil control well and if
this number was at least twice the number of the nil control well.
The immunoresponse of each individual was considered adequate
if the number of spots in the positive control was 20 or more. The
IFN-c in Health Care Workers
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the positive control well was less than 20 and if the antigen specific
wells were negative.
QuantiFERON-TB-GOLD In Tube
Briefly, a total of 3 ml of blood was drawn for each patient in
three tubes of 1 ml each (nil control, positive control and M.
tuberculosis specific antigens [ESAT-6, CFP-10 and TB7.7]).
Samples were incubated with the stimulating antigens during
16–24 h at 37uC. Afterwards, plasma samples were harvested and
the amount of IFN-c released was measured by an enzyme-linked
immunosorbent assay (ELISA), according to the manufacturer’s
instructions. Raw optical densities were interpreted by using
specific software provided by the manufacturer. The result
obtained in the nil control was subtracted from the mitogen
control and the antigen stimulated samples. The cut off value for a
positive test was 0.35 IU/mL of IFN-c in the sample after
stimulation with the specific antigens, regardless of the result of the
mitogen control. The result of the test was considered indetermi-
nate if an antigen-stimulated sample was negative and if the value
of the positive control was less than 0.5 IU/ml after subtraction of
the value of the nil control.
Prolonged T cell stimulation test
The prolonged T cell stimulation test was performed using a
protocol previously described and validated to our requirements
[36]. The assay was performed with frozen PBMCs, that were
thawed and resuspended in 10 ml of RPMI medium (Invitrogen,
Auckland, N.Z.). Later, cells were washed and cultured in
complete medium (90% RPMI and 10% FBS [PAA Laboratories
GmbH, Pasching, Austria] supplemented with penicillin and
streptomycin) in wells of 96-well round-bottomed microtiter plates
at 37uC with 5% CO2. For each patient we prepared three
different cell cultures. In the first culture, cells were incubated in
the absence of antigen (medium alone); in the second one
stimulated with ESAT-6 (Panel A); and in the last one with
CFP-10 (Panel B). The final volume of each culture was 0.5 mL.
After 3 and 6 day incubation period, 0.25 mL of each culture
supernatant was removed and replaced with fresh complete
medium supplemented with recombinant human interleukin (rIL)-
2 (Roche Diagnostics GmbH, Mannheim, Germany) at a final
concentration of 5 U/mL. On day 8, cells were washed one time
and cultured again in complete medium without rIL-2. On day 9,
250,000 cells were transferred by well to an ELISPOT plate and
stimulated with medium alone (negative control), phytohaemag-
glutinin (positive control), ESAT-6 (Panel A) and CFP-10 (Panel B)
during 16–20 hours at 37uC with 5%CO2. On day 10, ELISPOT
assay was developed according to manufacturer’s instructions.
Statistical analysis
Concordance between both tests was assessed using the Kappa
coefficient. Kappa (k) values below 0.40 indicate weak correlation,
values of 0.41–0.60 indicate good agreement and values above
0.60 indicate strong agreement. The difference in means was
detected using Students’ t-tests. The difference between number of
positives (percentage) among different groups was assessed using
Pearson’s Chi-square test. Risk factors for a positive test result
were defined using an odds ratio (OR). To adjust for multiple
variables we used a logistic regression model with IFN-c tests and
TST results as the outcomes. All variables included in the
multivariate analysis were determined a priori based on an
estimation of their significance during the unvariate analysis and
biological plausibility. Differences were considered significant
when the p value was less than 0.05. All analyses were performed
using the SPSS statistical software for windows (SPSS version 15.0;
SPSS Inc, Chicago, IL, USA).
Results
A total of 147 HCWs agreed to take part in the study, and 129
of them (87.1%) were screened with TST at least once in the past.
As shown in Table 1, the majority of the participants were women
(76.9%) and the median age was 43.3 (range: 22–63 years). Only
23 of the HCWs (15.6%) had received BCG vaccination. The
mean duration of years spent in the health care profession was
18.4 (range: 1–43 years), and the exposure was particularly high in
16 cases (10.9%).
95 HCWs (64.6%) had a previous positive TST and were not
re-tested. The positive TST result was obtained in 9 cases (9.5%)
in the last 5 years, in 10 cases (10.5%) in the last 5 to 9 years, in 14
cases (14.7%) in the last 10 to 14 years, in 59 cases (62.1%) more
than 14 years ago, and in 3 cases (3.2) the date was not reported.
Of the 52 HCWs with a previous negative TST or who were tested
for the first time, 8 (15.4%) resulted TST positive, and 44 (84.6%)
were TST negative.
When we excluded the individuals with previous positive TST,
the number of positive results for T-SPOT.TB was 12/52 (23.1%);
and for QFN-G-IT, 9/52 (17.3%) (Figure 1). The overall
agreement between T-SPOT.TB and TST excluding the patient
with indeterminate IFN-c result was 92.1% (47/51) (k:0.754;
se:0.11) and between QFN-G-IT and TST it was 98% (50/51)
(k:0.929; se:0.07). The agreement between the T.SPOT.TB and
the QFN-G-IT was 90.2% (46/51) (k:0.702; se:0.12). Only 4
HCW were BCG-vaccinated in this subgroup (Table 2).
Among individuals with a previous positive TST, the number of
positive results for T-SPOT.TB and QFN-G-IT was 45/95
(47.4%) and 34/95 (35.8%), respectively (Figure 1). Regarding
BCG status the number of positive results for T-SPOT.TB in
BCG-vaccinated individuals was 7/19 (36.8%) and in non BCG-
vaccinated was 33/70 (47.1%). For QFN-G-IT, the number of
positive results in BCG-vaccinated was 4/19 (21.1%) and in non
BCG-vaccinated population it was 28/70 (40.01%) (Table 2).
In non BCG vaccinated HCWs with a previous positive TST,
we evaluated, by both univariate and multivariate analysis
(Table 3), the relationship between a positive IFN-c tests and
the risk factors for LTBI. In univariate analysis (P=0.03; OR: 3.0;
95% Confidence interval [CI]: 1.13–8.15), as well as, in
multivariate analysis (P=0.03; OR: 3.67; 95%CI: 1.07–12.59),
only the occupational degree exposure was significant when the
outcome was a positive T-SPOT.TB result. For QFN-G-IT, the
occupational degree exposure was important but not statistically
significant (OR: 2.62; 95%CI: 0.81–8.42).
The diameter of TST induration was important in the
univariate analysis in both IFN-c tests, but not significant. The
highest diameter of indurations had the greatest percentage of
positive IFN-c tests; however, only 29 of the 95 HCW with
previous positive TST had the diameter of induration registered.
On the other hand, the results showed no significant association
between positive IFN-c tests and years since the previous positive
TST. Nevertheless, the number of responder T cells and the
amount of IFN-c released was higher in the HCWs with previous
positive TST results performed in the last 5 years (data not shown).
Of the non BCG-vaccinated HCWs with a previous positive
TST and a negative IFN-c test, a prolonged T cell stimulation test
was performed in 24 of them to detect remote infection. In 14
cases the test was not valid because there were not enough cells
recovered after the thawing process. For the remaining 10
samples, in 8 cases, although the controls ran well, no response
IFN-c in Health Care Workers
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6686Table 1. Participants characteristics (n=147).
Individuals without previous
positive TST
1 (n=52)
Individuals with previous
positive TST (n=95) Total (n=147)
n% n % n %
Gender
Women 40 76.9 73 76.8 113 76.9
Men 12 23.1 22 23.2 34 23.1
Age
18–29 7 13.5 1 1.1 8 5.5
30–39 29 55.7 14 14.8 43 29.3
40–49 13 25.0 38 40.0 51 34.6
.50 3 5.8 42 44.1 45 30.6
Years in the health care profession
1–4 7 13.5 1 1.1 8 5.5
5–9 8 15.4 6 6.3 14 9.5
10–14 17 32.7 7 7.4 24 16.3
15–24 16 30.7 44 46.3 60 40.8
.24 4 7.7 37 38.9 41 27.9
BCG vaccination
No 48 92.3 73 76.8 121 82.3
Yes 4 7.7 19 20.0 23 15.6
Unknown 0 0 3 3.2 3 2.0
Occupational TB
2 degree exposure
Low 20 38.5 48 50.5 68 46.3
Medium 24 46.1 39 41.1 63 42.8
High 8 15.4 8 8.4 16 10.9
Job category
HCW
3 51 98.1 83 87.4 134 91.2
No HCW 1 1.9 12 12.6 13 8.8
TST results
Negative 44 84.6 0 0 44 29.9
Positive 8 15.4 95 100.0 103 71.1
Diameter induration TST
,5 m m 4 48 4 . 6 004 4 2 9 . 9
5–9 mm 5 9.7 16 16.8 21 14.3
10–14 mm 1 1.9 10 10.5 11 7.5
.14 mm 2 3.8 4 4.2 6 4.1
Unknown 0 0 65 68.5 65 44.2
T-SPOT.TB
Negative 39 75.0 49 51.6 88 59.9
Positive 12 23.1 45 47.3 57 38.8
Indeterminate 1 1.9 1 1.1 2 1.3
QFN-Gold-IT
4
Negative 43 82.7 59 62.1 102 69.4
Positive 9 17.3 34 35.8 43 29.3
Indeterminate 0 0 2 2.1 2 1.3
1Tuberculin skin test;
2Tuberculosis;
3Health care Worker;
4QuantiFERON-TB Gold In Tube.
doi:10.1371/journal.pone.0006686.t001
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Quantiferon-TB Gold In Tube; PST: Prolonged stimulation test; POS: Positive; NEG: Negative; IND: Indeterminate.
doi:10.1371/journal.pone.0006686.g001
Table 2. Agreement between the tuberculin skin test, T-SPOT.TB and QuantiFERON-TB Gold In Tube in the different group of
patients (excluding indeterminate results).
TST
1 vs T-SPOT.TB TST vs QFN-G-IT
2 T-SPOT.TB vs QFN-G-IT
Agreement (%) Kappa SE Agreement (%) Kappa SE Agreement(%) Kappa SE
All subjects (n=143) 90/143 (62.9) 0.321 0.061 84/143 (58.7) 0.288 0.052 123/143 (86.0) 0.692 0.063
BCG vaccination (3 excluded)
Non BCG vaccinated 76/117 (64.9) 0.349 0.07 74/117 (63.2) 0.345 0.06 101/117 (86.3) 0.701 0.068
BCG vaccinated 11/23 (47.8) 0.169 0.09 8/23 (34.7) 0.085 0.05 20/23 (86.9) 0.650 0.177
Subjects without previous
positive TST result (n=51) 47/51 (92.1) 0.754 0.11 50/51 (98.0) 0.929 0.07 46/51 (90.2) 0.702 0.123
BCG vaccination
Non BCG vaccinated 43/47 (91.5) 0.749 0.116 46/47 (97.8) 0.928 0.07 41/47 (87.2) 0.695 0.125
BCG vaccinated 4/4 (100) - - 4/4 (100) - - 4/4 (100) - -
Subjects with previous
positive TST result (n=92) 43/92 (46.7) - - 34/92 (36.9) - - 77/92 (83.7) 0.668 0.077
BCG vaccination (3 excluded)
Non BCG vaccinated 33/70 (47.1) - - 28/70 (40.0) - - 59/70 (84.2) 0.682 0.087
BCG vaccinated 7/19 (36.8) - - 4/19 (21.0) - - 16/19 (84.2) 0.627 0.183
SE: standard error.
1Tuberculin skin test;
2QuantiFERON-TB Gold In Tube.
doi:10.1371/journal.pone.0006686.t002
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cell assay, rendering a negative result. In 2 cases, response against
both ESAT-6 and CFP-10 was detected in one case, and only
against CFP-10 in the other case. Therefore, the results suggested
that in the 20% of cases these individuals were infected in the past.
Concordance between both test results and association with known
risk factors for LTBI were also analysed in all the population included
in the study. TST was positive in 71.1% (103/147) (Figure 1). Table 4
shows the risk factors associated with a positive TST result. Univariate
analysis showed a statistically significant association between positive
TST, age and number of years in health care profession (p=0.001).
Interestingly, the non-HCWs showed a higher rate of TST and IFN-c
tests positivities than that shown by HCW. The most likely explanation
is that non-HCWs were significantly older than HCWs (P=0.013),
with the mean and SD being 50.4 years (9.5) and 42.6 years (8.7),
respectively.There wasalso association withprevious BCGvaccination
(OR: 2.37; 95%CI: 0.75–7.46) and gender (OR: 1.80; 95% CI: 0.72–
4.55), but the associations were not statistically significant.
Positive T-SPOT.TB results were obtained in 38.8% of all
studied HCW (57/147) in comparison with 29.3% for QFN-G-IT
(43/147). T.SPOT.TB was indeterminate in 2 cases and QFN-G-
IT was indeterminate in other 2 cases (Figure 1). Table 4 shows the
risk factors associated with a positive IFN-c tests result. On
univariate analysis, age, gender and degree of occupational
exposure were statistically significant for positive T-SPOT.TB
results; in contrast, for QFN-G-IT, only the age was statistically
significant. Gender and degree of occupational exposure were
important factors but were not statistically significant (OR: 2.0;
95%CI: 0.91–4.63; and OR: 1.82; 95%CI: 0.88–3.80, respectively).
In the multivariate analysis, age showed significant association for
positive TST (OR: 1.26; 95%CI: 1.05–12.20) and QFN-G-IT (OR:
1.15; 95%CI: 1.05–1.25) and T-SPOT.TB (OR: 1.14; 95%CI: 1.05–
1.24), but occupational TB degree showed significant association only
for positive IFN-c tests (OR: 4.59; 95%CI:1.68–12.51; and OR: 2.72;
95%CI: 1.04–7.13, respectively).
Data on agreement between the TST and IFN-c test results
were available for 143 participants (not including the 4
indeterminate results) (Table 2). The highest number of positive
IFN-c tests was obtained in patients with positive TST over
10 mm, although the differences in the number of positive IFN-c
tests in patients with a TST between 5–9 and over 10 mm were
not significant. Regarding the BCG-vaccination status, the overall
agreement in the non-vaccinated population was higher than in
the BCG-vaccinated population, but the k values indicate weak
agreement in both cases (Table 2). The difference in concordance
between TST and QFN-G-IT in non BCG and BCG vaccinated
HCWs was significant (P=0.021); in contrast, between TST and
T-SPOT.TB; and between both IFN-c tests it was not significant
(P=0.189 and P=0.801, respectively).
Discussion
Serial TST testing as part of a surveillance of HCWs may induce a
boosting phenomenon complicating the TST interpretation. A booster
reaction may occur as a result of remote M. tuberculosis infection,
infection with NTM or prior BCG vaccination [37,38]. In individuals
who undergo serial TSTs, it is possible that, after a negative result in
the initial TST, a positive result in the second year of testing may have
been the result of a boosted reaction. Although the booster
phenomenon is less frequent if the second test is administered more
than 2 months after the first TST, it has been described after intervals
of 1 year [35,39] and possible longer [37].
Table 3. Association between tuberculosis risk factors and positive T-SPOT.TB and QuantiFERON-TB Gold In Tube results in non
BCG vaccinated subjects with previous positive tuberculin skin test (n=70) by means of univariate and multivariate analysis.
Risk factors T-SPOT.TB QFN-G-IT
4 T-SPOT.TB QFN-G-IT
Positive n (%)
OR (CI 95%)
unadjusted Positive n (%)
OR (CI 95%)
unadjusted
OR (CI 95%)
adjusted
OR (CI 95%)
adjusted
Gender
Women 24 (42.1) 1 21 (36.8) 1 1 1
Men 9 (69.2) 3.09 (0.85–11.27) 7 (53.8) 2.0 (0.59–6.75) 0.27 (0.06–1.18) 0.60 (0.16–2.25)
Age years - 1.01(0.95–1.07) - 1.03 (0.96–1.09) 1.08 (0.97–1.22) 1.09 (0.98–1.22)
Occupational TB
1 degree exposure
Low 13 (34.2) 1 12 (31.6) 1 1 1
High 19 (61.3) 3.0 (1.13–8.15) 15 (48.4) 2.03 (0.76–5.42) 3.67 (1.07–12.59) 2.62 (0.81–8.42)
Years since the previous
positive TST
2
- 1.02 (0.97–1.07) - 0.99 (0.94–1.05) 1.03 (0.97–1.10) 0.98 (0.92–1.04)
Years in health care profession - 0.97 (0.92–1.04) - 1.0 (0.95–1.07) 0.92 (0.82–1.02) 0.96 (0.86–1.06)
Diameter of TST induration
5–10 mm 4 (33.3) 1 4 (33.3) 1 - -
.10 mm 5 (50.0) 2.0 (0.35–11.23) 5 (50.0) 2.0 (0.35–11.2) - -
Job category
Non HCW
3 5 (55.6) 1 3 (33.3) 1 1 1
HCW 28 (45.9) 0.67 (0.16–2.77) 25 (41.0) 1.38 (0.31–6.08) 0.67 (0.10–4.15) 0.51 (0.07–3.56)
CI: Confidence interval; OR: Odds ratio.
1Tuberculosis;
2Tuberculin skin test;
3Health care worker;
4QuantiFERON-TB Gold In Tube.
doi:10.1371/journal.pone.0006686.t003
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the TST for the diagnosis of LTBI in HCWs. The IFN-c tests have
potential advantages, beyond greater specificity. These include
logistical convenience (only require one visit to the healthcare
facility, the test result can be available within one day), more
objective interpretation of the results, and the ability to perform
serial testing without inducing the boosting phenomenon.
When considering HCWs without previous positive TST only, the
prevalence of LTBI in this study by IFN-c tests was higher (T-
SPOT.TB: 23.1%, and QFN-G-IT: 17.3%) than by TST (15.4%) with
an excellent level of agreement. In univariate analysis, age and number
of years in heath care profession were associated with an increased risk
for a positive TST. In contrast, for positive IFN-c tests associations
were found with age and the degree of occupational exposure and were
not related to previous BCG vaccination. These findings are consistent
with previous studies showing that an increased degree of exposure
[23,40], and age [27,41] were significant risk factors for positive QFN-
G tests. Contrary to our results, several studies obtained more positive
results by TST than by QFN-G tests, although in the majority of cases
the results could be explained by the effect of prior BCG vaccination
[23,24,26,27,41]. Barsegian et al [42] obtained a 1% of positive results
by T-SPOT.TB in German radiologist HCWs, and a 34% and 27% of
positive TST using.5m m o r .10 mm as a cut off, respectively.
Authors found that the induration of the TST was significantly higher
by foreign births (P,0.001) (all HCWs studied came from areas with a
high TB incidence) and previous TST (P=0.001). Although BCG
vaccination did not reach significance, the induration size in vaccinated
HCWs increased threefold. In contact studies involving HCWs, TST
also obtained a higher number of positive results than QFN-G,
however this is attributed to the impact of the BCG vaccination
[43,44]. It has been described that a positive QFN-G result was
associated with higher exposure groups [45].
Interestingly, the excellent concordance between T-SPOT.TB
and QFN-G-IT with TST (92.1% and 98%, respectively) in
patients without previous positive TST, falls dramatically to 46.7%
and 36.9%, respectively when compared to those HCWs with
previous positive TST. A proportion of negative IFN-c test cases
could be explained by the lack of specificity of TST, with some of
the previous positive TST being false-positive results as a
consequence of prior BCG vaccination or NTM infection [5].
Indeed, the agreement between TST and IFN-c test results in non
BCG vaccinated HCWs was higher than in BCG vaccinated
individuals. Furthermore, we have to consider as potential
explanation the fact that we cannot confirm the accuracy of the
previous positive TST results performed in other institutions,
because the tests were not done under study conditions, and
maybe some of them were erroneously considered as positive (the
milimetres of induration of the previous positive TST were not
recorded). Another limitation is that we have not repeated the
TST in the HCWs with a previous positive TST. Therefore, in
these individuals we have not compared the results of the IFN-c
with the current TST result. In this respect we asked some HCWs
about the possibility of repeating the TST and they all refuse.
However, although the capacity to respond positively to tuberculin
does no remain constant over the course of an individual’s lifetime,
and that it can weaken over time; it can never fully disappear.
These specific facts could introduce a bias to the study adding
false-positive TST results, and thereby increasing discordance.
However, another interesting hypothesis resides in the fact that TST
is able to detect both remote and recent TB infection while IFN-c tests
only detect recent infection [28,46,47]. This is because after an
overnight incubation only activated effector memory T cells that are
present in the circulation while the antigen is not cleared have enough
time to produce IFN-c. In contrast, the longer intradermal stimulation
of PPD might evoke central memory T cells. Consequently, the IFN-c
released by central memory T cells could be produced and detected by
in vitro methods after a prolonged stimulation. Therefore, HCWs
infected in the past would not respond to M. tuberculosis antigen
Table 4. Association between tuberculosis risk factors and positive tuberculin skin test, T-SPOT.TB and QuantiFERON-TB Gold In
Tube results by means of univariate analysis.
Risk factors TST
1 T-SPOT.TB QFN-G-IT
2
Positive n(%)OR (CI 95%) P
Positive n
(%) OR (CI 95%) P
Positive n
(%) OR (CI 95%) P
Gender
Women 74 (67.3) 1 NS 35 (31.8) 1 0,004 29 (26.4) 1 NS
Men 26 (78.8) 1.80 (0.72–4.55) 20 (60.6) 3.2 (1.47–7.37) 14 (42.4) 2.0 (0.91–4.63)
Age years - 1.18(1.11–1.25) 0.0001 - 1.04(1.0–1.08) 0.03 - 1.04(0.99–1.08) 0.05
Occupational tuberculosis degree exposure
Low 48 (70.6) 1 NS 20 (29.4) 1 0,04 16 (23.5) 1 NS
High 52 (69.3) 0.94 (0.46–1.93) 35 (46.7) 2.1 (1.05–4.19) 27 (36.0) 1.82 (0.88–3.80)
Years in health care profession - 1.12(1.06–1.18) 0.0001 - 1.0(0.97–1.04) NS - 1.0(0.96–1.05) NS
BCG vaccination
No 78 (66.7) 1 NS 45 (38.5) 1 NS 37 (31.6) 1 NS
Yes 19 (82.6) 2.37 (0.75–7.46) 7 (30.4) 0.7 (0.26–1.83) 4 (17.4) 0.45 (0.14–1.43)
Job category
Non HCW
2 12 (92.3) 1 NS 7 (53.8) 1 NS 4 (30.8) 1 NS
HCW 88 (67.7) 0.17.(0.02–1.38) 48 (36.9) 0.5 (0.16–1.58) 39 (30.0) 0.97 (0.28–3.32)
NS: Non significant differences; OR: Odds ratio; CI: Confidence interval.
1Tuberculin skin test;
2QuantiFERON-TB Gold In Tube;
3Health care worker.
doi:10.1371/journal.pone.0006686.t004
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prolonged incubation period [28,30,36,46,48]. Leyten et al [46]
described that among TST positive patients with a history of exposure
to M. tuberculosis, a 6-day lymphocyte stimulation test was more
frequently positive (92% of cases) than the T-SPOT.TB (46%) and
QFN-G-IT (33%) with the usual overnight stimulation. In our
experience, the 10-day stimulation assay in non-BCG vaccinated
HCWs with a previous positive TST and negative IFN-c tests was
positive in the 20% (2/10) of cases, suggesting that these patients were
infected with M. tuberculosis in some point in the past. Pollock et al [28]
reported 19% (7/36) of positive results after an extended stimulation
assay in TST-positive HCWs with a negative QFN-G and T-
SPOT.TB result. Ferrand RA [48] reported that the 6-day T cell
responses to ESAT 6 were greater than responses obtained by ex vivo
short-stimulation ELISpot. Recently, Schuck et al [49] exploring new
antigens to be candidate biomarkers of LTBI, detected that, in contrast
to the short-term single stimulation assay, latency-associated antigens
induced IFN-c expression in memory T cells from the majority of
LTBI in the long-term re-stimulation assay.
Although, the hypothesis that short-incubation mainly detects
recent or ongoing infection by M. tuberculosis, while prolonged-
incubation tests seem to be more sensitive for the diagnosis of
LTBI has not been totally demonstrated, the published results and
our own results make the theory plausible. Indeed, there are
findings in accordance with this line of thought from a study of
hepatitis C virus showing that short-term ELISPOT responses
were not influenced by depletion of memory cells, while the
depletion of these memory cells did decrease the antigen-specific
responses after prolonged culture [50].
Given that the risk of developing active TB is higher in the first
2 years after infection, the detection of recent TB infection by
means of IFN-c tests in HCWs (mainly immunocompetent) seems
to be very useful for targeting the high risk population that really
need LTBI.
In our experience, we have detected 5 HCWs with a positive result
by IFN-c test (4 by T-SPOT.TB, and 1 by QFN-G-IT) and a negative
TST. These results could be considered as a false-positive IFN-c result,
or as a true LTBI not detected by TST. Indeed, this kind of
discrepancy has been previously obtained by other authors. Nienhaus
et al [27] in a study that comprised 261 HCWs with exposure to M.
tuberculosis, 40% of positive QFN-G-IT had negative TST; and
Herrmann et al [43], in a contact study involving HCWs, described
that, in 2 of 19 cases QFN-G-IT was positive and TST negative. In our
study, the patients with negative TSTs and positive IFN-c tests showed
no sign of active TB and were allocated to a 6-month clinical follow-up,
without medical therapy. We have continued monitoring the 4 cases
with negative TST and positive T-SPOT-TB (the HCW with a
negative TST and positive QFN-G-IT stopped working at our
institution), and today, 4 years later, all remain healthy, their TST
continue to be negative, the T-SPOT-TB is positive in 2 cases, but
revert to negative in the other 2 cases. Reversion of QFN-G-IT results
[25] has been previously described in a follow-up cohort study of
Indian HCWs, although the authors explained that these reversions
w e r er e l a t e dt ob o r d e r l i n ep o s i t i v er e s u l t so fQ F N - G - I Ta tt h eb a s e l i n e
determination. In our study, the two reversions are not associated with
a previous borderline T-SPOT-TB result. In one case, the initial
response to ESAT-6 and CFP-10 antigens was 4 and 14 SFCs/
250,000 cells, respectively, and in the second determination no
response was detected. In the other case, the initial response to ESAT 6
antigen was 38 SFCs/250,000 cells, and against the CFP10 antigen
was 35. In the second determination after 4 years the no response
against the ESAT 6 antigen stimulation was produced, and against
CFP-10 antigen only 4 SFCs/250,000 was detected. In addition,
spontaneous clearance of TB infection cannot be rejected [51].
The use of IFN-c tests for serial follow-up of HCWs in order to
detect recent infection and avoid the booster effect seems to be an
alternative to TST. However, some factors should be taken into
consideration: Firstly, it has also been reported that levels of IFN-c
measured by QFN-G-IT remain persistently elevated after treatment
for LTBI among HCWs in India [52]. Secondly, Choi et al [53] have
described in HCWs QFN-G-IT conversion 2–4 weeks after
performing a TST test in positive TST population, but not in the
negative ones. Recently, van Zyl-Smit et al [54] have also reported
some IFN-ctests result conversions on day 7 after TST administration.
However, they stated that when using a two-step screening strategy it
appears safe to develop IFN-c tests within 3 days of performing the
TST. Richeldi et al [55] did not obtain conversion after performing
serial TST in negative TST individuals either. Nevertheless, the
HCWs who need serial testing will be those with previous negative
TST. For serial testing of negative TST HCWs the IFN-c will be
appropiate [25,53], although further investigation is required.
The main limitation of our study is that we have included a
small number of HCWs that allowed the detection of a limited
number of significant associations between some risk factors and
IFN-c positivity, especially in patients with a previous positive
TST. Nevertheless, despite this limitation, the results obtained are
sufficiently consistent to draw conclusions. Our paper not only
corroborates the previously published data confirming the use of
QFN-G-IT as an in vitro test for detecting LTBI in HCWs, but,
additionally, we provide new information regarding the use of the
T-SPOT.TB and its agreement with the QFN-G-IT and TST
highlighting its capacity to detect remote versus recent infection.
In summary, both IFN-c tests showed a similar number of
positive results, the concordance between the tests was excellent.
In addition, none of the tests were affected by prior BCG
vaccination. The decision to select T-SPOT.TB or QFN-G-IT in
HCW population will depend essencially on the resources
available. The in vitro tests required an expert laboratory with
trained personnel. The results indicate that the IFN-c tests are a
useful tool for detecting recent infection in HCWs population. The
use of IFN-c tests in the follow-up of negative TST HCWs
requires further studies which analyze the meaning of the
conversions and reversions results.
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